for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

U.S. FDA approves Novartis' lung cancer treatment

May 6 (Reuters) - Novartis AG on Wednesday got U.S. approval for its drug Tabrecta, to treat patients with a form of lung cancer, according to the U.S. Food and Drug Administration’s website.

The drug has been approved to treat non-small cell lung cancer that has spread to other parts of the body, the FDA said. (bit.ly/2YGybmg)

The drug got a priority review from the FDA in February. (Reporting by Manas Mishra in Bengaluru; Editing by Shounak Dasgupta)

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up